Tulare Lake earned the nickname "ghost lake" because it vanished over a century ago after its water was diverted for farming.

According to the comprehensive analysis, the aplastic anemia market, valued at approximately USD 270 million in 2023 across ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.< ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Regeneron has leveraged its monoclonal antibody ... but over the next few years we expect most of its sales to shift to long-acting Eylea HD, a higher-dose formulation. Starting in 2025, the ...

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...